MedPath

Intraperitoneal Administration of Fosfomycin, Metronidazole and Molgramostim Versus Intravenous Antibiotics for Perforated Appendicitis

Phase 2
Completed
Conditions
Appendicitis Perforated
Interventions
Registration Number
NCT03435900
Lead Sponsor
Herlev Hospital
Brief Summary

The objective of this trial is to evaluate if intraoperative intraperitoneal administration of fosfomycin, metronidazole and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) followed by oral antibiotic for three days is as effective as the current intravenous antibiotic treatment given during and three days after appendectomy for perforated appendicitis. The primary outcome is the total length of hospital stay, defined as the number of hours in hospital after end of operation and until 30-day follow-up.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
13
Inclusion Criteria
  • Age ≥18 years
  • Suspicion of acute appendicitis and planned for diagnostic laparoscopy and eventual laparoscopic appendectomy
  • Perforated appendicitis (diagnosed during surgery by the surgeon)
  • Negative p-HCG (women)
  • Written informed consent after written and verbal information (preoperatively for the intervention group and postoperatively for the control group)
Exclusion Criteria
  • Cannot understand, read or speak Danish
  • Previous allergic reaction to fosfomycin, metronidazole, rhGM-CSF, or penicillins e.g. piperacillin or amoxicillin
  • Diagnostic laparoscopy revealing normal appendix not requiring an appendectomy or appendicitis without perforation
  • Other intra-abdominal pathology requiring surgical intervention at the same operation
  • Known renal or hepatic disease or biochemical evidence at the time of admission
  • Known hematologic disease in current medical treatment
  • American Society of Anesthesiologists (ASA) physical status ≥4 (a patient with severe systemic disease that is a constant threat to life)
  • Body weight >110 kg
  • Surgery converted to open appendectomy
  • Anticipated compliance problems

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control groupStandard antibiotics intravenously-
Intervention groupCombination of fosfomycin, metronidazole and rhGM-CSF (administered together intraperitoneally) and three days of antibiotics p.o.-
Primary Outcome Measures
NameTimeMethod
Total length of hospital stayFrom end of surgery until 30-days follow-up

in hours

Secondary Outcome Measures
NameTimeMethod
Gastrointestinal Quality of Life Index (GIQLI)10 days (±2 days) and 30 days (±3 days) postoperatively

A disease-specific questionnaire validated in Danish is collected at 10 days postoperatively (±2 days) and at 30 days postoperatively (±3 days)

Postoperative complicationsFrom end of surgery until 30-days follow-up

Number. According to the Clavien-Dindo grading

Intraabdominal abscesses requiring drainageFrom end of surgery until 30-days follow-up

Number. It is defined as an organ/space surgical site infection according to CDC

CostsFrom end of surgery until 30-days follow-up

The estimated total costs of admission, surgery, possible complications, reoperations etc. in the two treatment groups.

Surgical site infections requiring surgical drainageFrom end of surgery until 30-days follow-up

It is defined as deep incisional surgical site infection according to Centre for Disease Control and Prevention (CDC)

Time to return to normal activitiesFrom end of surgery until 30-days follow-up

Time period in days. The date is defined at the time point at which the participant could return to normal daily activities.

Side effectsWithin 24 hours after surgery and 10 days (±2 days) postoperatively

Number and description. A questionnaire regarding side effects is collected within the first 24 hours after surgery and at 10 days postoperatively (±2 days)

ReadmissionsFrom end of surgery until 30-days follow-up

Number. Only readmissions related to the surgery will be registered; e.g. admission and treatment of a non-related condition will not be registered.

ReoperationsFrom end of surgery until 30-days follow-up

Number. Only reoperations related to the appendectomy will be registered.

Period of sick leave "absence from work"From end of surgery until 30-days follow-up

Time periode in days. The parameter is defined as the number of days from the operation to the time point at where the participant returned to work or school.

Adverse eventsFrom end of surgery until 30-days follow-up
Microbiological flora and susceptibilityFrom end of surgery until 30-days follow-up

Number and type of positive specimens. If participants have a postoperative infectious complication.

Trial Locations

Locations (2)

Department of Surgery, Bispebjerg Hospital

🇩🇰

Copenhagen, Denmark

Department of Surgery, Herlev Hospital

🇩🇰

Herlev, Denmark

© Copyright 2025. All Rights Reserved by MedPath